This is an automatically translated article.
Pertuzumab is a drug belonging to the group of monoclonal antibodies, anti-cancer drugs. Pertuzumab is prepared as a concentrated solution for infusion of 30mg/dl, 14ml vial equivalent to 420mg. So what disease does Pertuzumab treat? The article about this drug below will help you answer this question.
1. Uses of the drug Pertuzumab
Pertuzumab cancer treatment is indicated in the treatment of problems related to breast cancer.
Metastatic breast cancer: Pertuzumab in combination with Herceptin and docetaxel is used in patients with metastatic breast cancer or non-resectable, HER2-positive, HER2-positive, untreated breast cancer. anti-HER2 therapy or chemotherapy for metastatic cancer. Drugs used in neo-adjuvant treatment of breast cancer: Pertuzumab, a drug combined with Herceptin and chemotherapy, has a good effect in neo-adjuvant therapy for patients with HER2-positive, locally advanced tumors. , treatment of inflammation or early breast cancer.
2. How is Pertuzumab used correctly?
Pertuzumab is a prescription drug, use must be according to the prescription of a specialist. The information below is for reference only and cannot completely replace a doctor's prescription.
2.1. How to use Pertuzumab is only used to treat patients by intravenous infusion.
Pertuzumab has no antibacterial preservatives. Therefore, the sterility of the solution for infusion must be ensured, and must be performed by medical personnel, using sterilization techniques. The drug should be taken from the vial and diluted in a PVC or non-PVC polyolefin bag containing 250 ml of 0.9% NaCl infusion. Do not remove saline from the infusion bag because it can cause infection. For the initial dose, 2 vials of the drug are required and after dilution, the concentration of the drug in the solution is 3.0 mg/ml. For the next dose, 1 vial is required, and after dilution, the concentration of the drug in the solution is 1.6 mg/ml. When mixing Pertuzumab, it is important to note the following points:
The drug must be diluted by medical staff, the patient must not arbitrarily mix the drug. Absolutely do not use Dextrose solution to mix medicine. Mix the sachet by gently inverting it to avoid foaming. Dilution must be used immediately, and must be visually inspected for deposits and discolouration before administration to the patient. 2.2. Dosage Patients treated with Pertuzumab should be HER2-positive. So what is HER2 positive?
HER2 positive is defined as having a score of 3+ on the IHC or a ratio >2.0 on the ISH as assessed by a validated test. To ensure reliable results, tests should be performed in specialized laboratories, ensuring the authenticity of the testing process.
Pertuzumab when indicated will be used in combination with Herceptin and docetaxel.
The recommended starting dose of Pertuzumab is 840 mg intravenously over 60 minutes, followed 3 weeks later by a dose of 420 mg infused over 30-60 minutes. When co-administered with Pertuzumab, Herceptin is recommended as an intravenous infusion at an initial dose of 8 mg/kg over 90 minutes scheduled every 3 weeks, followed by every 3 weeks thereafter at a dose of 6 mg/kg within 30 - 90 minutes. The drugs should be administered sequentially. These two drugs can be given in any order. When patients receive docetaxel, this dose must be administered after Pertuzumab and Herceptin. Time of drug treatment for the following subjects:
Metastatic breast cancer: Use the drug to treat until the disease progresses or the toxicity cannot be controlled, then stop taking the drug. Neoadjuvant treatment of breast cancer: Pertuzumab should be used for 3 to 6 cycles depending on the selected treatment regimen. 2.3. When should the dose be adjusted? In case the patient discontinues Herceptin treatment, Pertuzumab should be discontinued. If docetaxel is stopped, the patient can still use Pertuzumab and Herceptin to treat the disease until the disease progresses or the toxicity cannot be treated. Dose reduction with Pertuzumab and Herceptin is not recommended.
3. Some notes when using Pertuzumab
In order to improve the traceability of biologic medicinal products, the trade name of the drug should be clearly indicated in the patient's medical record.
When patients use Pertuzumab, it is necessary to note some of the following cases:
Decreased left ventricular function: When using the drug for patients with a history of heart failure, there may be conditions leading to functional impairment. left ventricle such as uncontrolled hypertension, myocardial infarction, severe ventricular arrhythmias requiring treatment,... Embryotoxicity: Pertuzumab used in pregnant women can cause oligohydramnios, delay in amniotic fluid. fetal kidney development, and fetal death. Therefore, pregnant women should not use Pertuzumab for treatment. Hypersensitivity reactions / anaphylaxis : During the course of taking the drug, patients should be closely monitored to recognize hypersensitivity reactions to promptly handle. Pertuzumab is contraindicated in patients who have had a hypersensitivity reaction to the drug or to any of its ingredients. Use in children: The drug has not been studied in children under 18 years of age.
4. What side effects can patients experience when using Pertuzumab?
The drug causes anemia, neutropenia. Cardiovascular disorders: left ventricular dysfunction, congestive heart failure. Drugs causing eye disorders: increased tear secretion. Gastrointestinal disorders: diarrhea, nausea, vomiting, gastritis, constipation. Systemic disorders and injection site conditions: Fatigue, mucositis, asthenia, fever, peripheral edema. Immune system disorders: hypersensitivity to the drug, hypersensitivity reactions such as skin redness, erythema, swelling at the injection site. Skin and subcutaneous tissue disorders: Alopecia, rash, nail disorders, itching, dry skin. Shortness of breath, pleural effusion, insomnia, respiratory disorders, dizziness, headache, muscle pain, joint pain,... When experiencing abnormal symptoms, the patient should stop using the drug. Depending on the severity or lightness, there is an appropriate treatment. With mild cases, often just stopping the drug can ensure safety for the patient. In case the patient has a severe hypersensitivity reaction or allergic reaction, it is necessary to conduct supportive treatment by keeping ventilation, using epinephrine, breathing oxygen, using antihistamines, corticosteroids,... effective treatment for breast cancer patients. However, this is a drug that must be used under the prescription of a specialist, the patient should not self-medicate. In addition, the drug is administered by infusion, so it should be administered by medical personnel. Patients should strictly follow the instructions of the specialist to achieve the best treatment effect.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
